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Abstract 
         Schizophrenic patients have cognitive impairments, but gender differences in these 
cognitive deficits have had limited study. This study assessed cognitive functioning in 
471 subjects including 172 male and 78 female schizophrenic patients and 141 male 
and 130 female healthy controls. We found that immediate memory, language, delayed 
memory and total RBANS scores were significantly decreased in schizophrenia 
compared with healthy controls for both genders. Male patients had significant lower 
immediate memory, delayed memory and total RBANS scores than female patients, and 
healthy controls showed a similar gender difference. The RBANS showed modest 
correlations with PANSS scores, duration of illness and antipsychotic dose 
(chlorpromazine equivalents). Almost all RBANS scores in the schizophrenics and 
healthy controls showed significant positive correlations with education. Thus, patients of 
both sexes with schizophrenia experienced more deteriorated performance than healthy 
controls on cognitive domains of immediate memory, language and delayed memory. 
Furthermore, male schizophrenic patients had more serious cognitive deficits than 
female patients in immediate and delayed memory, but not in language, visuospatial and 
attention indices. 
 
Keywords:  schizophrenia; RBANS; PANSS; cognitive deficits; correlation; gender 
difference 
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1. Introduction 
         Neuropsychological studies of patients with schizophrenia have demonstrated 
cognitive deficits as core features of the illness. Cognitive deficits rather than clinical 
diagnostic categories may better represent the underlying pathogenesis of schizophrenia 
(Gur et al., 2007). Several studies have focused on gender differences in the cognitive 
deficits of schizophrenia and showed gender differences in cognitive domains in both 
schizophrenia and healthy populations (Goldstein et al., 2002; Halari et al., 2006; Phillips 
and Silverman, 1997; Ragland et al., 1999; Wisner et al., 2011). Furthermore, gender 
differences in schizophrenia’ cognitive deficits are evident in the prodromal symptoms, 
acute psychotic episodes, illness course, and clinical response to antipsychotic 
treatment (Grigoriadis and Seeman, 2002; Hughes et al., 2003; Rubin et al., 2008).  
         The explanations and hypotheses about the gender differences in cognitive tasks 
in both schizophrenia and healthy populations include abnormalities in brain structure 
and volume, abnormal function of neurotransmitter systems, gonadal hormone 
differences and genetic effects (Antonova et al., 2004; Friston et al., 1991; Stefansson et 
al., 2009; Wegesin and Stern, 2007). However, the evidence is still not clear whether 
gender differences occur in the cognitive deficits of schizophrenia patients. For example, 
some studies have reported that male patients appear to have more cognitive 
impairment than females (Goldstein et al., 1998; Seidman et al., 1997), while others 
have found that female schizophrenics exhibit greater cognitive deficits than males 
(Lewine et al., 1996). Moreover, some studies failed to find any sex differences in 
cognitive deficits of schizophrenia (Goldberg et al., 1995; Hoff et al., 1998). These 
conflicting results suggested that further study of the sex differences in the cognitive 
deficits of schizophrenia might benefit from examination in another non-Western culture 
such as China. 
       The inconsistency of gender differences in cognitive deficits relate to variations in 
illness severity, inadequate sample size,  sampling bias, and lack of normal healthy 
controls of females for statistically robust comparisons (Goldstein et al., 1998; Halari et 
al., 2006; Walker and Lewine, 1993). This study was specifically designed to test for the 
gender differences in cognitive functioning in a large sample of schizophrenia and 
healthy controls. To our knowledge, this is the first study examining gender differences 
in cognition in Chinese schizophrenic population. Also, the samples were taken so that 
the gender, age and education of the schizophrenic subjects matched the healthy 
controls.  
       The purpose of this study was to determine: (1) whether Chinese patients with 
chronic schizophrenia had cognitive deficits compared to healthy controls; (2) whether 
cognitive functioning in schizophrenia showed gender differences; (3) whether cognitive 
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deficits correlated with symptoms of schizophrenia, duration of illness, or antipsychotic 
treatments (chlorpromazine equivalents).  
 
2. Methods 
2.1. Subjects 
         We compared 200 (122 males, 78 females) physically healthy Chinese patients 
who met DSM-IV for schizophrenia to 271 (141 males, 130 females) healthy controls. All 
schizophrenic patients were inpatients of Beijing Hui-Long-Guan Hospital, a Beijing City 
owned psychiatric hospital and were chronic with at least 5 years of illness and were 
between 25 and 70 years old. They had been receiving stable doses of oral neuroleptic 
medications for at least 12 months prior to entry into the study. Their antipsychotic 
treatment consisted mainly of monotherapy with clozapine (n=101), risperidone (n=43), 
and other typical antipsychotics (n=56) including haloperidol (n=20), perphenazine 
(n=15), sulpiride (n=14) and chlorpromazine (n=7). In addition, 58 patients received 
antiparkinsonian drugs. 
       For comparison, healthy controls were recruited from the community, and group 
matched for age, education and gender. All subjects were Han Chinese recruited at the 
same period from the Beijing area. The patients and healthy subjects had a similar 
socioeconomic status and dietary patterns. We obtained a complete medical history and 
physical examination from all subjects, and any subjects with serious medical 
abnormalities were excluded. Neither the patients with schizophrenia nor the control 
subjects suffered from drug abuse or dependence. A psychiatrist ruled out any mental 
disorders among healthy controls by direct psychiatric interview; however, he did not use 
a structured interview instrument.  All subjects provided signed, informed consent to 
participate in this study, which was approved by the Institutional Review Board, Beijing 
Hui-Long-Guan Hospital. 
2.2. Clinical assessment 
         Two psychiatrists who had over five year clinical practice and who were blind to the 
clinical status and treatment conditions assessed the patient’s psychopathology using 
the Positive and Negative Syndrome Scale (PANSS)  (Kay et al., 1987). To ensure 
consistency and reliability of rating, the two psychiatrists simultaneously attended a 
training session for standardizing their use of the PANSS prior to the start of the study. 
Thereafter, they maintained an intraclass correlation coefficient of greater than 0.8 on 
the PANSS at repeated assessments during the course of this study. 
2.3. Cognitive measures 
         We individually administered The Repeatable Battery for the Assessment of 
Neuropsychological Status (RBANS) to measure cognitive function (Duff et al., 2008). 
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The RBANS is comprised of 12 subtests that are used to calculate 5 age-adjusted index 
scores and a total score (Abe et al., 2009). Test indices are immediate memory 
(comprised of list learning and story memory tasks); visuospatial/constructional 
(comprised of figure copy and line orientation tasks); language (comprised of picture 
naming and semantic fluency tasks); attention (comprised of digit span and coding 
tasks); and delayed memory (comprised of list recall, story recall, figure recall, and list 
recognition tasks).  Our group previously translated RBANS into Chinese and the clinical 
validity and its test-retest reliability established among controls and schizophrenic 
patients (Zhang et al 2009). To ensure consistency and reliability of rating, the two 
clinical psychologists simultaneously attended a training session for standardizing their 
use of the RBANS prior to the start of the study. Thereafter, they maintained an 
intraclass correlation coefficient of 0.92 on the RBANS at repeated assessments.  
       Each subject came in the testing room on a separate day to have a research 
member introduce our research center and be given a training session to allow the 
individual to become acclimated to the testing environment and computerized tasks. In 
order to reduce or eliminate the withdrawal effect of smoking, participants who smoked 
were allowed to smoke cigarettes prior to testing and during breaks. The subjects took 
breaks for smoking at the end of each domain test of the RBANS, in order to prevent 
participants from being in a state of nicotine withdrawal (Zhang et al 2012). The RBANS 
test was performed within the same timeframe for patients and controls.  
2.4. Statistical analysis 
      Group comparisons on demographic and clinical variables used chi squared or 
Fisher exact tests for categorical variables and Student t-tests or analysis of variance 
(ANOVA) for continuous variables. For the RBANS comparisons, we also included age, 
education and smoking as covariates in multivariate analyses of covariance for 
significant gender differences across the dependent measures from the RBANS total 
score and its five cognitive domains, with independent predictors being gender (male vs. 
female), diagnosis (patients vs. healthy controls) and the gender-by diagnosis interaction. 
Effect sizes were also calculated for the two-way comparisons and represented the 
mean difference, in standard deviation units, between groups of interest. Correlations 
between variables used Pearson product moment correlations with Bonferroni 
corrections applied to adjust for multiple testing. Multiple regression models were used to 
quantify the amount of variance in cognitive functioning explained by psychopathological 
variables, after controlling for several potential confounders, e.g., gender, age, years of 
education, and clinical variables. SPSS version 15.0 was used to do all statistical 
analysis.  Data were presented as mean±SD. All p values were 2 tailed at the 
significance level of <0.05. 
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3. Results 
3.1. Sample characteristics 
         Table 1 shows no significant differences between schizophrenics and healthy 
controls in age, sex and education. However, there was a significant difference in 
smoking rates between the patients (50.5%) and normal controls (37.3%) (x2 = 8.22, df= 
1, p<0.005). Furthermore, smoking was more common in male than female 
schizophrenic patients and in male than female controls (both P values <.001). 
Furthermore, significantly more male chronic schizophrenic patients than older male 
controls smoked (79.5% vs 61.7%); however, fewer female chronic schizophrenic 
patients than older female controls currently smoked (5.1% vs 10.8%) (both P values 
<.01). Thus, we controlling for smoking in the following analyses.  
      In addition, we found no significant differences between male and female patients in 
any of PANSS scores, duration of illness, or antipsychotics dose (equivalent to 
chlorpromazine) (Table 2). Furthermore, there were no gender differences in the ratio of 
first generation antipsychotics to second generation antipsychotics (p=0.55) or in the use 
of anti-Parkinson's medication between patients on these two types of medication 
(p=0.66) (Table 2).  We also found no difference in medication compliance between the 
two types of antipsychotics. In addition, there were no gender differences in 
antipsychotic monotherapy versus polytherapy (p<0.05). However, there was a 
significant gender difference in the times and duration of hospitalization (Table 2), which 
we controlled for in the following analyses.  
3.2. Cognitive performance in schizophrenia and healthy controls 
         Table 3 showed cognitive test scores in schizophrenic compared to control 
subjects on the RBANS total scores and all five indexes. After controlling for age, 
education and smoking, multivariate analysis of covariance revealed statistically 
significant differences between schizophrenic patients and controls for all cognitive 
domains (F1,464 =28.6, P<.0001). Furthermore, diagnosis (patient vs control) differences 
were significant for the RBANS total scores and all index scores (all P values <.001), 
except for the RBANS visuospatial/constructional index (p=.097) (Table 3). Pair-wise 
post hoc comparisons showed significant differences in the RBANS total score and all 
index scores (all p<0.001) between the male patients and male controls (all p<0.05-
p<0.001) with effect sizes ranging from 0.27 to 1.07 except for the 
visuospatial/constructional index, and between the female patients and female controls 
(all p<0.05-p<0.001), with effect sizes ranging from 0.25 to 0.93. After controlling for age, 
education, and smoking, multivariate analysis of covariance also revealed overall main 
effects for gender in RBANS immediate memory (F1,464= 28.82, P<.001; effect size=0.37), 
delayed memory (F1,464 =24.66, P<.001; effect size=0.54), and total score (F1,464 = 15.31, 
7 
 
 7
P<.001; effect size=0.36) domains. Women performed better than men on these 
domains.   
       Further multivariate analysis of covariance showed a gender×diagnosis interaction 
effect on for all cognitive domains (F1,464=2.25, p<0.05). In order to decompose the two-
way interaction, we examined patients and controls grouped by gender separately. Male 
patients performed worse than female patients on immediate memory, delayed memory, 
and RBANS total score (all p<0.05) (Table 3). After controlling for hospitalization and 
smoking separately, or together with duration of illness, clinical symptoms as assessed 
using the PANSS, antipsychotic medication (type, dosage and duration of treatment) and 
anti-Parkinson's medication, these differences still remained significant (all p<0.05). 
However, only the immediate memory result passed the Bonferroni test. In the control 
group, the males and females showed significant differences only in immediate memory 
(p<0.05) (Table 3). However, this result did not pass the Bonferroni test.   
3.3. Relationship between cognitive performance and clinical phenotypes in 
schizophrenia 
        Using multivariate regression analysis the following variables were independently 
associated with the RBANS total score: education (beta=0.24, t=4.02, p<0.001), PANSS 
negative symptom score (beta=-0.28, t=-3.71, p<0.001), and age (beta=-0.15, t=-2.39, 
p<0.05) and gender (beta=0.12, t=2.02, p<0.05). These factors together predicted 23% 
of the variance of the RBANS total score. 
         Further, data for the women and men with schizophrenia were analysed separately 
to assess gender differences in clinical characteristics associated with cognitive 
impairment.  We hypothesized that the clinical predicators for cognitive function were 
different in the male and female CS patients. In male patients, Pearson correlation 
analysis showed  significant negative associations between all examined cognitive 
variables and the negative symptom scale or PANSS total score (all p<0.01) (Table 4). 
Moreover, immediate memory, language and delayed memory were significantly and 
negatively associated with the general psychopathology scale (all p<0.01). In addition, 
the duration of illness had a significantly negative association with immediate memory, 
attention, delayed memory, and RBANS total score (all p<0.01). The RBANS total score 
had a significant negative relationship with antipsychotic dose (chlorpromazine 
equivalents) (Table 4). Finally, smoking was significantly and negatively associated with 
RBANS total score (r=-0.24, p<0.05) and the Visuospatial/Constructional index (r=-0.35, 
p<0.01). Further multivariate regression analyses showed that the following variables 
were independently associated with the RBANS total score: years of education 
(beta=0.29, t=3.62, p<0.001), PANSS negative symptom score (beta=-0.25, t=-2.41, 
p<0.05), and smoking (beta=-0.22, t=-2.29, p<0.05).  
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        In female patients, Pearson correlation analysis showed significant positive 
correlations between the positive symptom scale and immediate memory, visuospatial, 
and total score (all p<0.05) (Table 4). Except for the attention index, the other cognitive 
domains were negatively associated with the negative symptom scale (all p<0.05) (Table 
4). Immediate memory was positively associated with the general psychopathology scale 
(p<0.05). Only the language index was negatively associated with the duration of illness 
(p<0.05). Finally, we found a positive association between RBANS total score and 
antipsychotic dose (all p<0.05) (Table 4).  Further multivariate regression analyses 
showed that the following variables were independently associated with the RBANS total 
score: the PANSS negative symptom score (beta=-0.26, t=-2.30, p=0.024), the PANSS 
positive symptom score (beta=0.32, t=2.20, p=0.031) and age (beta=-0.21, t=-2.01, 
p=0.049).  
 
 
4. Discussion 
       This study had five major findings. (1) Significantly lower cognitive scores on the 
RBANS total score and nearly all of its subscales except for the visuospatial/ 
constructional index were found in schizophrenia than normal controls. (2) More 
specifically, male schizophrenics had significantly lower immediate memory, delayed 
memory and total RBANS scores than female schizophrenics. (3) The RBANS showed 
modest correlations with the PANSS scores, duration of illness and antipsychotic dose. 
(4) Lower education, higher negative symptoms, older age and male gender were 
associated with cognitive impairments in schizophrenia. (5) We found gender differences 
in the associations of specific cognitive impairments with various clinical characteristics 
and symptom assessments.  
       In this study, we found significant cognitive impairments for patients with 
schizophrenia. To our knowledge, this is the first report of cognitive deficits in immediate 
memory, language and delayed memory for Chinese patients with schizophrenia. These 
results are consistent with other phenomenological studies (Goldstein et al., 1998, Sota 
and Heinrichs, 2003, Halari et al., 2006). For example, abnormalities in the frontal lobe 
and hippocampal volume are associated with cognitive deficits in executive functioning, 
working memory, verbal fluency and immediate memory among schizophrenics (DeLisi 
et al., 1991, Antonova et al., 2004), suggesting that the cognitive deficits of 
schizophrenia may be associated with these brain abnormalities. Also, the cognitive 
deficits of schizophrenia were found to be associated with abnormal neurotransmitter 
systems in the brain and with genetic mutations (Friston et al., 1991; Stefansson et al., 
2009). Abnormal expression of neurotransmitter receptors occurs among schizophrenia 
9 
 
 9
in those brain regions that are related to cognitive deficits in verbal memory and 
attention (Crook et al., 2000; Newell et al., 2007; Sumiyoshi et al., 1996). For example, a 
reduction in M1 receptor protein in the hippocampus, superior temporal gyrus, and 
anterior cingulate cortex in schizophrenic subjects has been reported (Crook et al., 2000; 
Deng and Huang, 2005; Zavitsanou et al., 2004). A genetic study indicated that the 
homozygous risk AA genotype of ZNF804 performed significantly better on the cognitive 
tasks of verbal memory and spatial working memory than the homozygous CC genotype 
group (Walters et al., 2010). These studies suggest that multiple and complex 
mechanisms contribute to cognitive deficits in schizophrenia.  
        Male and female patients with schizophrenia did not differ on any PANSS scores, 
but immediate memory and delayed memory were worse in male than female 
schizophrenia, which we also found in our healthy controls. These discordant deficits in 
the clinical and cognitive domains of schizophrenics also were consistent with a previous 
study (Hughes et al., 2003). Similarly, these sex differences in cognitive domains are 
consistent with previous studies (Antonova et al., 2004; Halari et al., 2006; Sota and 
Heinrichs, 2003), and have been suggested as due to differences in brain structure for 
the two sexes and to differences in neural lateralization (Antonova et al., 2004). One 
study indicated greater right hemispheric specificity for males’ and bilateral 
representations for females’ brains (Gur et al., 2000) and greater leftward asymmetry of 
frontal lobe fractional anisotropy in females than males (Szeszko et al., 2003).  
       This female advantage in immediate and delayed memory may also reflect gonadial 
hormone effects on cognitive functioning. Estrogen and testosterone may influence 
cognitive functioning through dopamine and serotonin effects in specific brain regions 
(Fink et al., 1999; Hafner et al., 1991). For example, estrogen can decrease dopamine 
concentrations and modulate sensitivities and numbers of dopamine receptors in the 
striatum and hippocampus (Di Paolo, 1994; Karakaya et al., 2007; McEwen and Woolley, 
1994). Therefore, females may have better immediate and delayed memories than 
males. Female patients also may show better improvements in cognitive deficits with 
antipsychotic treatments potentially through normalizing estrogen’s activity in the brain 
(Grigoriadis and Seeman, 2002; Rubin et al., 2008).  However, not all studies have 
found sex differences in memory tasks and several have found sex differences in 
visuospatial and attention deficits in patients with schizophrenia (Goldstein et al., 1998; 
Halari et al., 2006).  
        Almost all cognitive indices were negatively correlated with the negative PANSS 
symptom scale in both sexes and with the general psychopathology scale and total 
PANSS scale in males. Fewer negative symptoms are perhaps not surprisingly 
associated with less impairment on cognitive tasks. The other significant negative 
10 
 
 10
associations between duration of illness and immediate memory, attention and delayed 
memory in male patients are perhaps intuitively obvious in suggesting that the more 
chronic patients perform worse on all these cognitive tasks. Whether this association is a 
pernicious effect of long term institutionalization, long-term medication side effects, or 
the course of this illness, which was originally called “dementia precox,” cannot be 
determined from our data.  
        The more interesting positive associations are between immediate or visuospatial 
memory and positive symptoms in females. Does being paranoid improve the patient’s 
capacity for these types of cognitive functions in female patients with schizophrenia? 
Perhaps it does, as the patient becomes hyper-vigilant and focused on specific tasks 
such as these cognitive tests rather than simply being unable to concentrate on anything. 
However, this is only speculation; we do not have evidence to support this hypothesis, 
which deserves further investigation.  Overall, the relationships between the cognitive 
tasks and PANSS scales and duration of the illness in schizophrenia are very complex. 
Furthermore, effects of antipsychotic drugs make these relationships more complex, 
since antipsychotic drug may can improve clinical symptoms and cognitive performance 
of schizophrenia, while controversially also having side effects on performance during 
cognitive tasks (Daban et al., 2005; Stip, 2006; Terry and Mahadik, 2007). For example, 
a study has showed that cognitive tasks may be potentially impaired after patients with 
schizophrenia were treated long-term using antipsychotic drugs (Terry and Mahadik, 
2007). However, other studies have not indicated that antipsychotics impair cognitive 
function in schizophrenia (Daban et al., 2005). More work is clearly needed on this topic 
with better controlled longitudinal studies. We are starting such studies in China.   
       Some studies indicate that cigarette smoking or nicotine may ameliorate some of 
the cognitive deficits in schizophrenic patients (Smith et al, 2002; George et al., 2002; 
Hahn et al, 2012), suggesting that cigarette smoking or nicotine serves as a form of self-
medication. However, in our present study, we found that smoking was negatively 
associated with RBANS total score and the Visuospatial/Constructional index in male 
patients.  Furthermore, the female patients, who overall had much lower rates of 
smoking than the males, had better cognitive functioning than the male patients.  Thus, 
smoking may be taken up and sustained by those with more cognitive impairment.  
Whether smoking then relatively improves their cognition would require a longitudinal 
study and cannot be addressed in our cross-sectional design. 
         This study has some limitations. First, our subjects were all inpatients and may 
represent more serious clinical profiles including more serious cognitive deficits than 
outpatient schizophrenics. Second, our patients are all chronic and might show gender 
differences due to long term gender differences in antipsychotic drug effects rather than 
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pathophysiological differences between the genders. Third, we had no data for 
medication free periods with these patients, which may affect the results of the cognitive 
performances. Thus, gender differences might be overestimated in this study. Fourth, 
psychiatric disorders were ruled out among healthy controls by an unstructured 
psychiatric evaluation, and no specific instrument was used to rule out diagnoses. 
         In conclusion, patients with chronic schizophrenia performed worse than healthy 
controls in immediate and delayed memory and language. Furthermore, among patients 
males have more serious cognitive impairments than females in immediate memory and 
delayed memory, but not in language, visuospatial and attention.  
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Table 1       
Demographics of schizophrenia and healthy controls grouped by gender* 
Groups Gender Age (years) Education (years) 
Schizophrenia Male (n=122) 51.6±8.7 9.4±2.4 
  Female (n=78) 53.5±7.7 9.9±2.5 
Healthy control Male (n=141) 48.6±10.9 9.4±3.2 
  Female (n=130) 50.1±10.0 9.3±3.5 
*Patient group did not differ from control group on any characteristic by X2 
test and ANOVA. 
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Table 2         
Characteristics of male and female patients with schizophrenia 
  Male Female t or X2 p-value 
Duration of illness (months) 144.8±101.2 128.1±114.4 1.08 0.28 
Antipsychotic types (typicals/atypicals) 36/86 20/58  0.35 0.55 
Antipsychotic dose (CPZ equivalents) 523.9±672.7 548.6±635.3 -0.26 0.80 
Duration of current antipsychotic treatment 53.8±51.4 53.5±72.6 0.036 0.97 
Antiparkinsonian drug (Yes/No)      34/88    24/54 0.19 0.66 
Hospitalization times       4.3±3.0     3.4±2.9 2.39 <0.01 
Duration of hospitalization (years)    10.8±9.8     8.7±8.5 2.13 <0.05 
Score on positive symptom scale    12.5±5.0   13.4±6.7 -1.09 0.31 
Score on negative symptom scale    22.1±7.0   20.6±7.3 1.41 0.16 
Score on general psychopathology scale    26.4±5.2   27.4±6.2 -1.17 0.24 
Total PANSS score 60.9±13.1 61.3±14.7 -0.20 0.84 
Fasting glucose 5.3±0.8 5.5±1.0 -1.91 0.06 
Note: Mean ± SD. CPZ=Chlorpromazine; PANSS= the Positive and Negative Syndrome Scale 
  
  
18 
 
 18
Table 3               
The levels of cognitive function in schizophrenia and healthy controls  
    
  Schizophrenia  Healthy control    
RBANS   Male (n=122) 
Female 
(n=78)  
 Male 
(n=141) 
Female 
(n=130) 
Diagnose 
F (p value)   
Gender 
F (p value) 
Diagnose*Gender 
F (p value) 
Immediate memory  59.9±18.1*++ 
    
66.7±19.6++  
    
73.0±16.6*   80.3±18.2 
 
69.48(<.001) 
 
21.85(<.001)
 
0.22(0.64) 
Visuospatial/constructional 81.4±18.5  85.6±19.1  80.2±14.7   80.5±15.8 3.81(0.059) 2.37(0.12) 1.42(0.23) 
Language 86.8±14.3++ 
    
86.3±15.6++    94.6±10.9   94.9±13.0 
43.50(<.001) 0.13(0.72) 0.61(0.44) 
Attention 81.8±15.1 82.1±15.9    85.5±17.2   87.2±21.7 9.62(0.002) 0.17(0.68) 0.82(0.37) 
Delayed memory 
       
66.6±20.3***++
    
77.5±20.7++    85.7±15.0   90.0±14.9 
98.65 (<.001) 21.19(<.001) 3.94(0.048) 
Total RBANS scores 68.6±16.0*++ 74.5±16.8+    79.1±12.8   82.3±16.0 50.16(<.001) 11.50(0.001) 0.39(0.53) 
* indicates the comparison between males and females in patients or in healthy controls: *p<0.05, **p<0.01, ***p<0.001. 
+ indicates the comparison between patient and healthy controls in males or females: + p<0.01, ++ p<0.001. 
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Table 4                
Correlations between the repeatable battery for the assessment of neuropsychological status (RBANS) and the positive and negative  
syndrome scale (PANSS), duration of illness or antipsychotic dose in patients with schizophrenia 
  Correlation With RBANS Score (r)  
  Immediate Visuospatial/ Language Attention Delayed  Total  
  memory constructional      memory RBANS 
   Index Index Index Index Index scores 
Male (n=122)             
Score on positive symptom scale       -0.01      0.01  -0.03     -0.09   -0.01  -0.03 
Score on negative symptom scale     -0.34***     -0.31***  -0.45***  -0.29*** -0.36***  -0.40*** 
Score on general psychopathology scale    -0.23**     -0.11  -0.28**     -0.16  -0.26**  -0.24** 
Total PANSS score    -0.28**     -0.20*  -0.36*** -0.25** -0.29***  -0.32*** 
Duration of illness      -0.33***     -0.2  -0.13 -0.25** -0.31***  -0.29*** 
Antipsychotic dose (CPZ equivalents) 0.03     -0.03   0.02      0.08   0.16  -0.22* 
Female (n=78)             
Score on positive symptom scale 0.29*      0.30**   0.20      0.04   0.19   0.29* 
Score on negative symptom scale -0.22*     -0.26*  -0.45***     -0.22  -0.31**  -0.35** 
Score on general psychopathology scale 0.23*      0.13  -0.09     -0.07   0.09   0.11 
Total PANSS score       0.12      0.06  -0.17     -0.12  -0.03   0.00 
Duration of illness      -0.12     -0.15  -0.25*     -0.20  -0.10  -0.18 
Antipsychotic dose (CPZ equivalents)       0.16      0.20   0.15      0.17   0.19   0.23* 
Note: chlorpromazine=CPZ. Pearson correlation analysis showed *p<0.05, **p<0.01, ***p<0.001.
  
 
 
